Harmony Biosciences Holdings Stock Return On Equity
| HRMY Stock | USD 33.23 0.44 1.34% |
Harmony Biosciences Holdings fundamentals help investors to digest information that contributes to Harmony Biosciences' financial success or failures. It also enables traders to predict the movement of Harmony Stock. The fundamental analysis module provides a way to measure Harmony Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Harmony Biosciences stock.
| Last Reported | Projected for Next Year | ||
| Return On Equity | 0.28 | 0.26 |
Harmony | Return On Equity |
Harmony Biosciences Holdings Company Return On Equity Analysis
Harmony Biosciences' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Harmony Biosciences Return On Equity | 0.23 |
Most of Harmony Biosciences' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Harmony Biosciences Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Harmony Return On Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Harmony Biosciences is extremely important. It helps to project a fair market value of Harmony Stock properly, considering its historical fundamentals such as Return On Equity. Since Harmony Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Harmony Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Harmony Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Harmony Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Harmony Biosciences Holdings has a Return On Equity of 0.2275. This is 100.95% lower than that of the Pharmaceuticals sector and 100.62% lower than that of the Health Care industry. The return on equity for all United States stocks is 173.39% lower than that of the firm.
Harmony Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Harmony Biosciences' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Harmony Biosciences could also be used in its relative valuation, which is a method of valuing Harmony Biosciences by comparing valuation metrics of similar companies.Harmony Biosciences is currently under evaluation in return on equity category among its peers.
Harmony Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Harmony Biosciences from analyzing Harmony Biosciences' financial statements. These drivers represent accounts that assess Harmony Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Harmony Biosciences' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.4B | 2.1B | 2.5B | 3.3B | 1.9B | 1.8B | |
| Enterprise Value | 2.4B | 2.0B | 2.4B | 3.2B | 1.8B | 1.9B |
Harmony Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Harmony Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Harmony Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Harmony Fundamentals
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 1.67 B | ||||
| Shares Outstanding | 57.03 M | ||||
| Shares Owned By Insiders | 11.62 % | ||||
| Shares Owned By Institutions | 92.82 % | ||||
| Number Of Shares Shorted | 6.06 M | ||||
| Price To Earning | 293.37 X | ||||
| Price To Book | 3.18 X | ||||
| Price To Sales | 2.78 X | ||||
| Revenue | 582.02 M | ||||
| Gross Profit | 354.37 M | ||||
| EBITDA | 216.39 M | ||||
| Net Income | 128.85 M | ||||
| Cash And Equivalents | 254.17 M | ||||
| Cash Per Share | 4.30 X | ||||
| Total Debt | 193.57 M | ||||
| Debt To Equity | 0.79 % | ||||
| Current Ratio | 4.91 X | ||||
| Book Value Per Share | 10.46 X | ||||
| Cash Flow From Operations | 219.39 M | ||||
| Short Ratio | 6.80 X | ||||
| Earnings Per Share | 2.11 X | ||||
| Target Price | 47.11 | ||||
| Number Of Employees | 246 | ||||
| Beta | 0.77 | ||||
| Market Capitalization | 1.9 B | ||||
| Total Asset | 811.45 M | ||||
| Retained Earnings | (143.28 M) | ||||
| Working Capital | 287.29 M | ||||
| Net Asset | 811.45 M |
About Harmony Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Harmony Biosciences Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Harmony Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Harmony Biosciences Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Harmony Stock Analysis
When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.